NYSE:RCUS - Arcus Biosciences Stock Price, Forecast & News

Arcus Biosciences trades on the New York Stock Exchange (NYSE) under the ticker symbol "RCUS."

Arcus Biosciences Inc (NYSE:RCUS) released its quarterly earnings results on Tuesday, November, 5th. The company reported ($0.51) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.49) by $0.02. The company had revenue of $1.75 million for the quarter, compared to analyst estimates of $1.34 million. Arcus Biosciences had a negative net margin of 1,180.37% and a negative return on equity of 38.73%. View Arcus Biosciences' Earnings History.

Arcus Biosciences is scheduled to release their next quarterly earnings announcement on Tuesday, March 3rd 2020. View Earnings Estimates for Arcus Biosciences.

5 brokerages have issued 1-year target prices for Arcus Biosciences' stock. Their forecasts range from $15.00 to $22.00. On average, they anticipate Arcus Biosciences' stock price to reach $19.25 in the next year. This suggests a possible upside of 17.1% from the stock's current price. View Analyst Price Targets for Arcus Biosciences.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arcus Biosciences in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Arcus Biosciences.

News stories about RCUS stock have been trending very negative on Monday, InfoTrie Sentiment reports. The research firm identifies negative and positive news coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Arcus Biosciences earned a media sentiment score of -3.0 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the next several days. View News Stories for Arcus Biosciences.

Some companies that are related to Arcus Biosciences include Axsome Therapeutics (AXSM), Intercept Pharmaceuticals (ICPT), PPD (SDGR), Myokardia (MYOK), Deciphera Pharmaceuticals (DCPH), Taro Pharmaceutical Industries (TARO), Insmed (INSM), Apellis Pharmaceuticals (APLS), ChemoCentryx (CCXI), Uniqure (QURE), Amicus Therapeutics (FOLD), Arena Pharmaceuticals (ARNA), ArQule (ARQL), Biohaven Pharmaceutical (BHVN) and Aurinia Pharmaceuticals (AUPH).

Based on aggregate information from My MarketBeat watchlists, some companies that other Arcus Biosciences investors own include Horizon Therapeutics (HZNP), BioDelivery Sciences International (BDSI), Agile Therapeutics (AGRX), Aduro BioTech (ADRO), Nabriva Therapeutics (NBRV), Senseonics (SENS), AcelRx Pharmaceuticals (ACRX), Amarin (AMRN), Melinta Therapeutics (MLNT) and vTv Therapeutics (VTVT).

(RCUS) raised $99 million in an initial public offering on Thursday, March 15th 2018. The company issued 7,100,000 shares at a price of $13.00-$15.00 per share. Citigroup, Goldman Sachs and Leerink Partners served as the underwriters for the IPO.

Arcus Biosciences' stock is owned by many different of institutional and retail investors. Top institutional investors include Invus Financial Advisors LLC (4.02%), Boxer Capital LLC (3.65%), EcoR1 Capital LLC (1.59%), State Street Corp (1.40%), Geode Capital Management LLC (0.86%) and Janus Henderson Group PLC (0.65%). Company insiders that own Arcus Biosciences stock include Juan C Jaen, Kathryn E Falberg and Terry J Rosen. View Institutional Ownership Trends for Arcus Biosciences.

RCUS stock was sold by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Platinum Investment Management Ltd., EcoR1 Capital LLC, Credit Suisse AG and New York State Common Retirement Fund. View Insider Buying and Selling for Arcus Biosciences.

RCUS stock was acquired by a variety of institutional investors in the last quarter, including Invus Financial Advisors LLC, Boxer Capital LLC, Algert Global LLC, Renaissance Technologies LLC, Prudential Financial Inc., California Public Employees Retirement System, Jacobs Levy Equity Management Inc. and Goldman Sachs Group Inc.. Company insiders that have bought Arcus Biosciences stock in the last two years include Juan C Jaen, Kathryn E Falberg and Terry J Rosen. View Insider Buying and Selling for Arcus Biosciences.

Shares of RCUS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of RCUS stock can currently be purchased for approximately $16.44.

Arcus Biosciences has a market capitalization of $753.92 million and generates $8.35 million in revenue each year. The company earns $-49,590,000.00 in net income (profit) each year or ($1.43) on an earnings per share basis. Arcus Biosciences employs 108 workers across the globe.View Additional Information About Arcus Biosciences.

The official website for Arcus Biosciences is http://www.arcusbio.com/.

Arcus Biosciences' mailing address is 3928 Point Eden Way, Hayward CA, 94545. The company can be reached via phone at 510-694-6200 or via email at [email protected]